Literature DB >> 15232708

Value of (124)I-PET/CT in staging of patients with differentiated thyroid cancer.

L S Freudenberg1, G Antoch, W Jentzen, R Pink, J Knust, R Görges, S P Müller, A Bockisch, J F Debatin, W Brandau.   

Abstract

The aim of this study is to evaluate the clinical significance of (124)I positron emission tomography (PET) using a combined PET/CT tomograph in patients with differentiated thyroid carcinoma and to compare the PET/CT results with (131)I whole-body scintigraphy (WBS), dedicated PET and CT alone. Twelve thyroid cancer patients were referred for diagnostic workup and entered complete clinical evaluation, including histology, cytology, thyroglobulin level, ultrasonography, fluorine-18 fluorodeoxyglucose (FDG)-PET, FDG-PET/CT and CT. Lesion-based evaluation showed a lesion delectability of 56, 87 and 100% for CT, (124)I-PET, and combined (124)I-PET/CT imaging, respectively. Lesion delectability of (131)I-WBS was 83%. We conclude that (124)I-PET/CT imaging is a promising technique to improve treatment planning in thyroid cancer. It is particularly valuable in patients suffering from advanced differentiated thyroid cancer prior to radio-iodine therapy and in patients with suspected recurrence and potential metastatic disease.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15232708     DOI： 10.1007/s00330-004-2350-0

Source DB:  PubMed          Journal:  Eur Radiol        ISSN： 0938-7994            Impact factor:   5.315


  18 in total

Review 1.  Combining anatomy and function: the path to true image fusion.

Authors:  D W Townsend; S R Cherry
Journal:  Eur Radiol       Date:  2001       Impact factor: 5.315

2.  Attenuation correction for a combined 3D PET/CT scanner.

Authors:  P E Kinahan; D W Townsend; T Beyer; D Sashin
Journal:  Med Phys       Date:  1998-10       Impact factor: 4.071

3.  FDG PET of recurrent or metastatic 131I-negative papillary thyroid carcinoma.

Authors:  N S Alnafisi; A A Driedger; G Coates; D J Moote; S J Raphael
Journal:  J Nucl Med       Date:  2000-06       Impact factor: 10.057

4.  Diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography in the follow-up of papillary or follicular thyroid cancer.

Authors:  L Hooft; O S Hoekstra; W Devillé; P Lips; G J Teule; M Boers; M W van Tulder
Journal:  J Clin Endocrinol Metab       Date:  2001-08       Impact factor: 5.958

5.  Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET.

Authors:  Susanne M Eschmann; Gerald Reischl; Kilian Bilger; Juergen Kupferschläger; Marcel H Thelen; Bernhard M Dohmen; Hariolf Besenfelder; Roland Bares
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-03-27       Impact factor: 9.236

6.  Investigational study of iodine-124 with a positron camera.

Authors:  R M Lambrecht; N Woodhouse; R Phillips; D Wolczak; A Qureshi; E D Reyes; C Graser; S Al-Yanbawi; A Al-Rabiah; W Meyer
Journal:  Am J Physiol Imaging       Date:  1988

7.  In vivo imaging of the human thyroid with a positron camera using 124I.

Authors:  P Frey; D Townsend; A Jeavons; A Donath
Journal:  Eur J Nucl Med       Date:  1985

8.  Combined PET/CT with iodine-124 in diagnosis of spread metastatic thyroid carcinoma: a case report.

Authors:  L S Freudenberg; G Antoch; R Görges; J Knust; R Pink; W Jentzen; J F Debatin; W Brandau; A Bockisch; J Stattaus
Journal:  Eur Radiol       Date:  2003-12       Impact factor: 5.315

9.  Tomographic imaging of the human thyroid using 124I.

Authors:  P Frey; D Townsend; A Flattet; R De Gautard; S Widgren; A Jeavons; A Christin; A Smith; A Long; A Donath
Journal:  J Clin Endocrinol Metab       Date:  1986-10       Impact factor: 5.958

10.  Role of initial iodine-131 whole-body scan and serum thyroglobulin in differentiated thyroid carcinoma metastases.

Authors:  M Filesi; A Signore; G Ventroni; F F Melacrinis; G Ronga
Journal:  J Nucl Med       Date:  1998-09       Impact factor: 10.057
View more
  28 in total

1.  (124)I in PET imaging: impact on quantification, radiopharmaceutical development and distribution.

Authors:  Andreas Bockisch; Lutz Freudenberg; Sandra Rosenbaum; Walter Jentzen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-11       Impact factor: 9.236

2.  Combined metabolic and morphologic imaging in thyroid carcinoma patients with elevated serum thyroglobulin and negative cervical ultrasonography: role of 124I-PET/CT and FDG-PET.

Authors:  L S Freudenberg; G Antoch; A Frilling; W Jentzen; S J Rosenbaum; H Kühl; A Bockisch; R Görges
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01-12       Impact factor: 9.236

Review 3.  Combined PET/MRI: a new dimension in whole-body oncology imaging?

Authors:  Gerald Antoch; Andreas Bockisch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03       Impact factor: 9.236

4.  Lobar mucinous bronchioloalveolar carcinoma of the lung showing negative FDG uptake on integrated PET/CT.

Authors:  Yon Mi Sung; Kyung Soo Lee; Byung-Tae Kim; Joungho Han; Eun Jeong Lee
Journal:  Eur Radiol       Date:  2005-02-17       Impact factor: 5.315

5.  Planar and SPECT imaging in the era of PET and PET-CT: can it survive the test of time?

Authors:  Abass Alavi; Sandip Basu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08       Impact factor: 9.236

Review 6.  Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer.

Authors:  Lutz S Freudenberg; Walter Jentzen; Alexander Stahl; Andreas Bockisch; Sandra J Rosenbaum-Krumme
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-12       Impact factor: 9.236

7.  The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET(/CT) imaging.

Authors:  Walter Jentzen; Dorothee Balschuweit; Jochen Schmitz; Lutz Freudenberg; Ernst Eising; Thomas Hilbel; Andreas Bockisch; Alexander Stahl
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-07-13       Impact factor: 9.236

8.  18F-fluorodeoxyglucose positron emission tomography in patients with recurrent ovarian cancer: in comparison with vascularity, Ki-67, p53, and histologic grade.

Authors:  Song-Mee Cho; Yong Gyu Park; Joon Mo Lee; Jae Young Byun; Jae Mun Lee; Kyo-Young Lee; Gyeong-Sin Park; Hyeon-Sook Kim; Bae Young Lee; Kang-Hoon Lee; Kyung-Sup Song
Journal:  Eur Radiol       Date:  2006-06-20       Impact factor: 5.315

Review 9.  Molecular imaging in thyroid cancer.

Authors:  T F Heston; R L Wahl
Journal:  Cancer Imaging       Date:  2010-01-20       Impact factor: 3.909

10.  ¹²⁴I PET/CT in the pretherapeutic staging of differentiated thyroid carcinoma: comparison with posttherapy ¹³¹I SPECT/CT.

Authors:  Cecile de Pont; Servais Halders; Jan Bucerius; Felix Mottaghy; Boudewijn Brans
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-01-23       Impact factor: 9.236
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.